Researchers sought to determine whether fixed-duration chemotherapy-free treatment with obinutuzumab and idelalisib would be effective in patients with R/R WM.
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
A year-end update on WM, a distinct entity of lymphoplasmacytic lymphoma presenting with monoclonal pleomorphic immunoglobulin M (IgM) proteins, was recently published in the American Journal of Hematology.
A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.
Zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with WM compared with ibrutinib.
Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.
